Please type a plus sign (+) inside this box ->		
--	--	--

PTO/SB/08A (08-00)
Approved se through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC Control of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MAR 0 5 2002 5

TRADFun

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

C	omplete if Known		
Application Number	09/778,926	<u> </u>	
Filing Date	February 6, 2001	C	Į.
First Named Inventor	John Collinge		Ž
Group Art Unit	1655		-
Examiner Name	Not Yet Assigned	- 20	H
Attorney Docket Number	102286.408CON	160	7

mns, Lines, elevant r Relevant Appear
 -
<u></u>

				FOR	EIGN PATENT DOCUMENTS	3		
Examiner Initials*	Cite No.1	Office	Foreign Patent Doo 3 Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
Ch	A1	WO	95/31466		Prusiner, S.B. et al.	11-23-1995		
	A2	wo	97/04814		Prusiner, S.B. et al.	02-13-1997		
11/4	А3	WO	97/46572		Prusiner, S.B. et al.	12-11-1997		
						•		
		1						

	/[n	<u> </u>		· · · · · · · · · · · · · · · · · · ·	<i></i>
Examiner Signature	form	Kr.	Chal	roabar)	1	Date Considered	3/1	18/02

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. ¹⁶ if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO



PTO/SB/08B (08-00) through 10/31/2002, OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required	to respond to a collection of information unless it contains a valid OMB control number.
	Complete if Known

	omplete if Known	
Application Number	09/778,926	
Filing Date	February 6, 2001	<u> </u>
First Named Inventor	John Collinge	_m_
Group Art Unit	1655	
Examiner Name	Not Yet Assigned	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) of 2 Sheet 2 **Attorney Docket Number** 102286.408CON

		OTHER ROLD ART. MON PATENT LITERATURE POSSIMENTS	
	1	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
xaminer nitials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1
AC	AA	Caughey, B. et al. "Binding of the Protease-Sensitive Form of Prion Protein PrP to Sulfated Glycosaminoglycan and Congo Red." J. of Virology 1994; 68(4):2135-41.	
	АВ	Fink, J.K. et al. "Detecting Prion Protein Gene Mutations by Denaturing Gradient Gel Electrophoresis." Human Mutation 4(1994):42-50.	
1	AC	Laplanche, J.L. et al. "Molecular genetics of prion diseases in France." Neurology 44(1994):2347-51.	
	AD	McKinley, M.P. et al. "A Protease-Resistant Protein is a Structural Component of the Scrapie Prion." Cell 35(1983):57-62.	Ť
	AE	Parchi, P. et al. "Molecular Basis of Phenotypic Variability in Sporadic Creutzfeldt-Jakob Disease." Annals of Neurology 1996; 39(6):767-77.	†
	AF	Williamson, R.A. et al. "Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein." Proc. Natl. Acad. Sci. USA 93(1996):7279-82.	†
Re	AG	Xi, Y.G. et al. "Detection of proteinase-resistant protein (PrP) in small brain tissue samples from Creutzfeldt-Jakob disease patients." J. of Neurological Sci. 124(1994):171-73.	
		·	+

Examiner Date Kr. Charrabash Signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.